Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below:
Joined April 2018
- Tweets 1,220
- Following 196
- Followers 14,761
- Likes 148
477 Photos and videos
Data published in @TheLancet evaluate an investigational oral therapy for the growing number of patients with relapsed/refractory #MultipleMyeloma using our CELMoD approach: bit.ly/4xLc24D #EHA2026
2
3
128
Today @ #EHA2026, catch Dr. Susan Bal’s (@SusanBal9) presentation on updated Phase 1 safety and efficacy results of an investigational GPRC5D #CART in #RRMM after 1–3 prior treatments.
Share your thoughts on how the #RRMM treatment landscape is evolving. bit.ly/4el1Dn9
113
Jun 12
A primary analysis of a BMS study presented at #EHA26 evaluates an EMA at the maximum-approved dose in patients with lower-risk MDS who are red blood cell transfusion dependent. bit.ly/4gityql
2
93
Jun 12
Explore how we’re advancing cell therapy, leveraging next-generation cell engineering and new approaches to expand what’s possible in hematologic malignancies: bit.ly/4onBlFx
#EHA2026 #ScienceFirsthand #OneBMS
1
82
Jun 11
Today at #EHA2026, Dr. Narendranath Epperla (@NEpperla) will share the results of a real-world study evaluating CD19 #CAR T cell therapy and bispecifics in 3L #LBCL. bit.ly/4ojIDKh
100
Jun 3
Don’t miss our session at #EULAR2026, where CAR T experts will discuss the emerging research in “immune reset” concept, and key considerations for B cell–targeted strategies, including patient selection in clinical trials. bit.ly/4x5irab
1
1
170
Jun 3
Join us at #EULAR2026, as we present new data from our translational research on the correlation between the tyrosine kinase 2 (TYK2) immune pathway and Sjögren’s disease manifestations. Learn more about immune signaling pathways: bit.ly/3PRg7mE
97
Jun 1
See how we’re advancing targeted protein degradation using three powerful approaches, CELMoD agents, ligand-directed degraders and degrader antibody conjugates, to drive innovation in cancer and beyond: bit.ly/43cf0AW
#ASCO26 #OneBMS
128
Jun 1
Join us at #ASCO26 as new Phase 3 data in triple-negative breast cancer (TNBC) is presented. Learn more: bit.ly/434KSY9
125
Jun 1
Today at #ASCO26, tune in for results from a large real-world study on the #CART treatment experience for 2L #LBCL across FACT and non-FACT centers in the United States.
Share your perspective on bringing CAR T closer to home for patients. bit.ly/4wX2P8P
1
1
134
May 31
At #ASCO26, new Phase 3 data in metastatic esophageal squamous cell carcinoma (ESCC) will be presented. Learn more: bit.ly/43AQAkD
114
May 29
Join us tomorrow at #ASCO26 as Dr. Solange Peters presents Phase 2 results from ROSETTA Lung-02. @peters_solange
Stop by or join the live stream from 1:21–1:27pm CDT. #LungCancer #BioNTech_Group
1
1
168
May 29
Join us tomorrow at #ASCO26 as Dr. Tiago Biachi de Castria presents ROSETTA CRC-203 TiP poster. @BiachiTiago
Join the poster session from 9am to 12pm CDT. #GICancer #BioNTech_Group
1
3
173
May 27
Breakthroughs in oncology are moving fast—but access is still determining who benefits from them.
On DoctoRx Unscripted, leading oncologists join Dr. Tania Small to explore what it will take to close that gap. Watch the full oncology series now: bit.ly/4tV3lkR
1
85
May 21
Nearly 70% of lung cancers are still diagnosed at an advanced stage, but science is changing what’s possible—giving some patients years of life back. Two leading oncologists join Dr. Tania Small to discuss how more patients can benefit. Watch now: bit.ly/4usEsOC
4
2,240
May 18
Melanoma incidence continues to rise, affecting diverse age groups. Early detection and awareness are vital for better outcomes.
Hear more about the realities of melanoma: bit.ly/4tM7J5M
#OneBMS #MelanomaAwarenessMonth
1
97
May 16
At #ATS2026, we're exploring the pathophysiology of #PulmonaryFibrosis, and the key role the lysophosphatidic acid (LPA-LPA1) pathway plays in epithelial cell injury, inflammation and fibrosis—all of which result in disease progression. Learn more: bit.ly/4nDzbkM #OneBMS
180
May 7
Endocannabinoids help regulate neuronal signaling. We’re exploring how inhibition of Fatty acid amide hydrolase (FAAH) and Monoacylglycerol lipase (MAGL) may impact endocannabinoid levels in conditions like Alzheimer’s disease. Learn more: bit.ly/4dbQ3u2 #OneBMS
172
Apr 21
Wrap up the last day of the #AACR2026 conference by stopping by the poster session to hear Dr. Jaclyn Neely’s presentation of the biomarker analyses from the RELATIVITY 104 trial.
Join the session from 9am to 12pm PST #LungCancer #NSCLC
1
1
282